News - Research, Ophthalmics

Filter

Current filters:

ResearchOphthalmics

Popular Filters

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

Israel’s OphthaliX updates on clinical developments and strategic plans

09-06-2014

Israel-based OphthaliX, a majority-owned subsidiary of biotech firm Can-Fite BioPharma focussed on ophthalmic…

BiotechnologyCan-Fite BioPharmaLicensingOphthaliXOphthalmicsResearch

US retinal specialists very receptive to pipeline agents for dry-AMD

US retinal specialists very receptive to pipeline agents for dry-AMD

05-06-2014

Surveyed US retinal specialists are highly willing to prescribe key emerging therapies for the treatment…

emixustatGlaxoSmithKlineGSK-933776Markets & MarketingOphthalmicsOtsukaPharmaceuticalResearchUSA

Novartis presents real world data for Lucentis

Novartis presents real world data for Lucentis

09-05-2014

Swiss drug major Novartis has reported data on the eye drug Lucentis (ranibizumab) at the 2014 Association…

AMDEuropeHealthLucentisMajorMedicineNovartisOphthalmicsOphthalmologyPharmaceuticalResearch

Eleven Biotherapeutics presents positive data on eye disease candidates

07-05-2014

US-based Eleven Biotherapeutics, a clinical-stage biopharmaceutical company developing protein therapeutics…

BiologyBiopharmaceutical company developing protein therapeuticsBiotechnologyCytokinesHealth Medical PharmaMedicineOphthalmicsResearchUSA

Shire 1st-qrt 2014 sales and earnings rocket; lifitegrast disappoints

01-05-2014

Ireland-headquartered drugmaker Shire posted a strong set of financials this afternoon, showing that…

FinancialLifitegrastOphthalmicsPharmaceuticalRare diseasesResearchShire

Santhera presents new efficacy data with Raxone for Leber's hereditary optic neuropathy

04-03-2014

Swiss specialty drugmaker Santhera Pharmaceuticals says that current data from the expanded access program…

OphthalmicsPharmaceuticalRaxoneResearchSanthera Pharmaceuticals

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Biocon and Quark Pharma collaborate on novel siRNA based therapeutics

18-12-2013

India-based biotech firm Biocon and the USA’s Quark Pharmaceuticals have entered into a licensing and…

BioconBiotechnologyLicensingOphthalmicsQuark PharmaceuticalsResearch

Stelis Biopharma and Pieris link up for novel Anticalin therapeutics in ophthalmology

18-12-2013

Stelis Biopharma (formerly Agila Biotech), a subsidiary of India’s Strides Arcolab, and privately-held…

GlobalLicensingOphthalmicsPharmaceuticalPieris AGResearchStelis BiopharmaStrides Arcolab

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease

09-12-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced mixed results from a Phase III efficacy…

EuropeLifitegrastOphthalmicsPharmaceuticalResearchShire

India and China to lead modest growth in Asia-Pacific ophthalmology drug market

India and China to lead modest growth in Asia-Pacific ophthalmology drug market

22-11-2013

The ophthalmology therapeutics market for dry eye syndromeand glaucoma in four Asia-Pacificcountries…

Asia-PacificMarkets & MarketingOphthalmicsPharmaceuticalResearch

Regeneron reports positive Phase III data for Eylea

Regeneron reports positive Phase III data for Eylea

22-10-2013

Regeneron Pharmaceuticals has announced positive results for Eylea Injection from the Phase III VIBRANT…

EyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronResearch

Oxford BioMedica gets US and French go-ahead to resume recruitment into ocular clinical trials

17-10-2013

Oxford BioMedica has received agreement from the US Food and Drug Administration and the French regulatory…

BiotechnologyEuropeOphthalmicsOxford BioMedicaRegulationResearch

Roche highlights late-stage pipeline beyond cancer

02-10-2013

Swiss drug major Roche has provided an update from its leading late-stage pipeline comprising 10 new…

Gastro-intestinalsKadcylalampalizumabOncologyOphthalmicsPharmaceuticalResearchRoche

Positive new data for Novartis drug Lucentis across four indications

Positive new data for Novartis drug Lucentis across four indications

27-09-2013

Novartis has presented new clinical and real world data for its ophthalmic agent Lucentis in more than…

EuropeLucentisNovartisOpthalmicsPharmaceuticalResearch

Bayer’s Eylea primary endpoint in two Phase III trials for DME

Bayer’s Eylea primary endpoint in two Phase III trials for DME

27-09-2013

Bayer (BAYN: DE) this morning said that Eylea has achieved the primary endpoint in two pivotal phase…

BayerEuropeEyleaOpthalmicsPharmaceuticalRegeneronResearch

Back to top